Vivos Therapeutics Inc.

NASDAQ: VVOS · Real-Time Price · USD
4.61
0.00 (0.00%)
At close: Aug 14, 2025, 3:59 PM
4.39
-4.77%
Pre-market: Aug 15, 2025, 08:53 AM EDT

Vivos Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
14.63M 15.03M 14.58M 14.02M 13.36M 13.8M 14.5M 15.45M 16.24M 15.84M 16.28M 16.58M 16.9M 16.89M 15.8M 14.54M 13.32M
Cost of Revenue
6.04M 6.01M 5.87M 5.75M 5.64M 5.68M 5.79M 6.13M 6.43M 6M 5.73M 5.34M 4.62M 4.28M 3.61M 2.96M 2.63M
Gross Profit
8.59M 9.02M 8.71M 8.28M 7.72M 8.12M 8.72M 9.31M 9.8M 9.84M 10.56M 11.25M 12.28M 12.6M 12.18M 11.58M 10.69M
Operating Income
-11.13M -11.03M -12.5M -13.35M -15.93M -17.3M -19.07M -20.99M -23.44M -25.26M -25.69M -25.79M -22.89M -19.47M -19.22M -15.53M -12.89M
Interest Income
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 31.46K 90.28K 109.25K 117K 101.51K 63.73K 66.48K
Pretax Income
-11.24M -11.14M -12.57M -12.04M -15.64M -13.58M -15.41M -18.75M -20.22M -24.03M -25.33M -25.35M -22.4M -20.29M -19.14M -15.5M -12.88M
Net Income
-11.24M -11.14M -12.57M -12.04M -15.64M -7.11M -10.15M -13.52M -15.01M -23.99M -36.96M -36.95M -33.97M -33.16M -19.14M -15.5M -12.88M
Selling & General & Admin
19.28M 19.61M 20.92M 21.33M 23.35M 24.94M 27.15M 29.64M 32.56M 34.42M 35.59M 36.35M 34.45M 31.34M 27.33M 23.06M 19.53M
Research & Development
100K 200K 200K 300K 400K 300K 200K 100K 100K 100K 100K 100K n/a n/a n/a n/a n/a
Other Expenses
291K 313K 318K 172K 27K 180K 344K 519K 519K 506K 505.23K 522.73K 717.5K 733K 742.1K 728.52K 714.39K
Operating Expenses
19.53M 19.86M 21.07M 21.48M 23.65M 25.42M 27.79M 30.31M 33.24M 35.09M 36.25M 37.03M 35.17M 32.08M 28.07M 23.79M 20.24M
Interest Expense
n/a n/a 3.3M 3.3M 3.3M 3.3M 26K 53K 81K 81K 59.18K 41.67K 13.92K 14K 27.72K 35.22K 53.04K
Selling & Marketing Expenses
1.44M 1.73M 1.93M 2.22M 2.49M 2.47M 3.22M 3.68M 4.79M 4.91M 4.87M 5.74M 5.44M 5.55M 5.05M 3.51M 2.61M
Cost & Expenses
25.76M 26.06M 27.09M 27.37M 29.29M 31.1M 33.58M 36.44M 39.68M 41.1M 41.98M 42.37M 39.78M 36.36M 31.69M 26.75M 22.88M
Income Tax Expense
n/a 1.44M 1.44M 1.44M 1.44M -6.48M -5.26M -5.24M -5.21M -41K 11.62M 11.55M 11.5M 12.8M -75.72K -30.43K -15.37K
Shares Outstanding (Basic)
8.6M 5.89M 6.62M 3.23M 2.31M 1.83M 1.2M 1.2M 990.56K 920.48K 849.34K 849.34K 849.32K 920.48K 833.06K 829.52K 728.42K
Shares Outstanding (Diluted)
8.6M 5.89M 6.62M 3.23M 2.31M 1.83M 1.2M 1.2M 990.56K 920.48K 849.34K 849.34K 849.34K 921.26K 833.06K 829.52K 728.44K
EPS (Basic)
-0.19 -1.37 -4.95 -6.3 -10.32 -3.87 -9.48 -14.16 -17.81 -27.58 -41.67 -41.79 -38.39 -38.11 -27.41 -24.49 -22.45
EPS (Diluted)
-0.19 -1.37 -4.95 -6.3 -10.32 -3.87 -9.48 -14.16 -17.81 -27.58 -41.65 -41.77 -38.37 -38.09 -27.41 -24.49 -22.45
EBITDA
-10.52M -10.59M -12.04M -13.03M -15.61M -16.8M -18.61M -20.35M -22.66M -24.31M -25.61M -25.63M -22.81M -19.56M -18.39M -14.76M -12.11M
EBIT
-11.15M -11.19M -12.65M -13.49M -16.07M -17.3M -17.89M -19.81M -22.25M -23.89M -26.4M -26.49M -23.59M -20.36M -19.2M -15.49M -12.83M
Depreciation & Amortization
612K 581K 586K 590K 593K 622K 642K 667K 681K 668K 667.23K 684.73K 717.5K 733K 742.1K 728.52K 714.39K